ResoTher Pharma
PrivateLast Round
Convertible Debt
Oct 28, 2026
Est. Valuation
$33M
Total Funding Raised
$2.73M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
ResoTher Pharma operates in Healthcare & Life Sciences and is based in Denmark. Its latest recorded funding round was a VC Round in July 2026.
ResoTher Pharma is a biotechnology company that develops peptide-based therapeutics intended for inflammation resolution in cardiovascular conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ResoTher Pharma Comparables
Compare ResoTher Pharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Serpin Pharma | 78% | |
| Novo Nordisk | 73% | |
| Epoqe Pharma | 73% |
For institutional investors. Book with your work email.
ResoTher Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Convertible Debt | Oct 28, 2026 | ||||
| Reverse Merger | Oct 28, 2026 | ||||
| VC Round | Jul 6, 2026 | ||||
| Grant | Nov 7, 2023 | ||||
| Private Placement | May 4, 2021 | ||||
Private Placement | Nov 1, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
ResoTher Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Axilium Capital | Private Placement |
| Innovation Fund Denmark | Private Placement |
| European Innovation Council Fund | Grant |
| North Finance A/S | Private Placement |
| European Commission | Private Placement |
| M Ventures | Private Placement |
| European Innovation Council | Private Placement |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 28, 2026
Raised $3.87M in convertible debt.
- Aug 22, 2026
Monthly visitors increased 633% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingNov 9, 2026
ResoTher Pharma ApS is developing RTP-026 to protect the heart in patients with acute myocardial infarction and is preparing a phase IIb study following phase IIa results in Sep '26.
- receives_financingSep 15, 2026
ResoTher Pharma ApS secures $6.55M in financing after promising results with a treatment for heart damage.
- is_developingSep 15, 2026
ResoTher Pharma ApS is developing a new class of resolution therapeutics in Denmark to activate the body’s natural mechanisms for resolving excessive inflammation and improve treatment options for acute hyperinflammatory disorders as of Sep 15th '26.
For institutional investors. Book with your work email.
ResoTher Pharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ResoTher Pharma's valuation, stock price, and market status.
Is ResoTher Pharma a public or private company?
ResoTher Pharma is a private company.
What is the current stock price of ResoTher Pharma?
ResoTher Pharma is a private company, so its shares have no public market price. Caplight tracks ResoTher Pharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ResoTher Pharma worth (valuation)?
ResoTher Pharma's valuation is estimated at $33.0M based on funding round data.
Can I buy ResoTher Pharma stock?
ResoTher Pharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ResoTher Pharma's last funding round?
ResoTher Pharma's most recent funding round was Convertible Debt on October 28, 2026.
Who are the main investors in ResoTher Pharma?
Key investors in ResoTher Pharma include Capnova.
Will ResoTher Pharma IPO soon?
No public IPO plans have been announced for ResoTher Pharma.
How can I track ResoTher Pharma secondary market activity?
Caplight tracks bids, offers, and trades in ResoTher Pharma's shares on secondary markets.